Thomas Gad: Yeah, thank you, Charles. So, I’ll just high level say that, yeah, when we see tumor uptake, the protocol has been designed to move the patient to a repeat protein dose and then a 200 millicurie dose. So that’s what happened with the patient, but I would like to relay this question over to you, Vignesh, and then provide a little more color and then look forward to the more details.
Vignesh Rajah: Yes. By inference, when we say [200] (ph), the patient has been dosed to 200 millicurie. As on the basis, data patient has shown positive imaging uptake as per the protocol. So as you — as mentioned earlier on, we’ve gone through cohorts 1 and 2, and we are now in cohort 3, with a higher dose of SADA protein at 1 milligrams per kilo. In terms of your other question, the imaging dose of radio isotope is 30 millicurie. And the therapeutic dose for this Part A at least is 200 millicurie. There is no planned imaging straight after the therapeutic dose. But, there’s sufficient granularity and imaging quality coming from the 30 millicure dose, at least to address the question that we have in terms of uptake in the vital organs and also clearance from the system. So again, we’re all evaluating this as we go forward. It’s still very early stages and we’ll provide more data when we provide more mature information at the end of this year in the R&D Day.
Charles Zhu: Sounds great. Thanks for that color and thanks for taking our questions and happy Friday.
Thomas Gad: Thank you.
Operator: Our next question comes from the line of Mike Ulz with Morgan Stanley. Please proceed with your question.
Mike Ulz: Hey guys, thanks for taking the question. Maybe just a bit of a follow-up on the launches outside the US and maybe you could talk about your thoughts on those market opportunities relative to the US over the long term? Thanks.
Thomas Gad: Yeah. So, talking about SciClone, our partnership in China and the approval that we got back in December, they have now announced — they launched the product over there, I think, late June, early July. So it’s obviously very, very new for us. But we do think that that’s going to be a material market for us going forward. But it’s too early to get some color on how that’s going to work. So we look forward to having two or three quarters. We know it’s initially a 40 hospital campaign with dedicated 15 FTEs. So we are quite excited about it. And GD2 in that market is obviously fairly new. I think the first GD2 antibody was introduced nine months ago, and we are the second on the market shortly thereafter. So that’s exciting as well.
Mike Ulz: Okay. Thank you.
Thomas Gad: With Brazil, we are currently in negotiations on pricing. And once that settles, we look forward for Adium to launch their [indiscernible] 50% in South America. That is also an exciting market for us. And our, I think we are very pleased with the progress of our WEP name patient program, in Europe and as well with Takeda on Israel and Swixx pharmaceuticals in Eastern Europe. So, it’s nice to see ex US sales also gaining momentum.
Mike Ulz: Great. Thanks.
Operator: Our next question comes from the line of Bill Maughan with Canaccord Genuity. Please proceed with your question.
Bill Maughan: Good morning and thanks. So looking down the line at a first-line indication for DANYELZA eventually. So if the study — if the induction study is positive and eventually you have a label, obviously, you’ll be one of two, GD2s in the first line, but there will be different settings in the first line induction versus consolidation. So given that it’s not just two options in a head to head competition for treatment, all else being equal, I just want to get your commentary on how you see the competitive dynamic playing out when you have two different drugs for kind of two different strategies for attacking first line neuroblastoma?
